QuiaPEG Pharmaceuticals Holding AB (publ) (QUIA.ST)
SEK 0.02
(0.0%)
SEK 0.02
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 2.17 Million SEK | -75.63% |
| 2022 | 8.9 Million SEK | 1590.32% |
| 2021 | 527 Thousand SEK | 117.64% |
| 2020 | -2.98 Million SEK | -143.46% |
| 2019 | 6.87 Million SEK | 15.12% |
| 2018 | 5.97 Million SEK | -21.94% |
| 2017 | 7.65 Million SEK | 1427.35% |
| 2016 | 501 Thousand SEK | -94.47% |
| 2015 | 9.06 Million SEK | 36.38% |
| 2014 | 6.64 Million SEK | -9.24% |
| 2013 | 7.32 Million SEK | 2.76% |
| 2012 | 7.12 Million SEK | -30.61% |
| 2011 | 10.27 Million SEK | 17.83% |
| 2010 | 8.71 Million SEK | -2.06% |
| 2009 | 8.9 Million SEK | 9.88% |
| 2008 | 8.1 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 1.13 Million SEK | 0.0% |
| 2024 Q1 | 1.13 Million SEK | 58.54% |
| 2023 Q4 | 714 Thousand SEK | 0.0% |
| 2023 Q1 | 371.5 Thousand SEK | -82.28% |
| 2023 FY | 2.29 Million SEK | -74.26% |
| 2023 Q2 | 371.5 Thousand SEK | 0.0% |
| 2023 Q3 | 714 Thousand SEK | 92.19% |
| 2022 FY | 8.9 Million SEK | 1590.32% |
| 2022 Q1 | 1.57 Million SEK | 265.37% |
| 2022 Q2 | 2.28 Million SEK | 45.51% |
| 2022 Q4 | 2.09 Million SEK | -29.07% |
| 2022 Q3 | 2.95 Million SEK | 29.27% |
| 2021 Q2 | 3.44 Million SEK | 14.58% |
| 2021 FY | 527 Thousand SEK | 117.64% |
| 2021 Q4 | -950 Thousand SEK | -733.33% |
| 2021 Q1 | 3 Million SEK | 778.1% |
| 2021 Q3 | -114 Thousand SEK | -103.31% |
| 2020 Q3 | -909 Thousand SEK | -456.47% |
| 2020 Q2 | 255 Thousand SEK | 134.98% |
| 2020 FY | -2.98 Million SEK | -143.46% |
| 2020 Q1 | -729 Thousand SEK | -128.76% |
| 2020 Q4 | -443 Thousand SEK | 51.27% |
| 2019 FY | 6.87 Million SEK | 15.12% |
| 2019 Q2 | 2.78 Million SEK | 1128.19% |
| 2019 Q1 | 227 Thousand SEK | 106.35% |
| 2019 Q4 | 2.53 Million SEK | 91.18% |
| 2019 Q3 | 1.32 Million SEK | -52.44% |
| 2018 Q1 | 2.02 Million SEK | -64.9% |
| 2018 FY | 5.97 Million SEK | -21.94% |
| 2018 Q4 | -3.57 Million SEK | -228.85% |
| 2018 Q3 | 2.77 Million SEK | -41.5% |
| 2018 Q2 | 4.74 Million SEK | 133.86% |
| 2017 FY | 7.65 Million SEK | 1427.35% |
| 2017 Q2 | 1.1 Million SEK | 266.89% |
| 2017 Q3 | 765 Thousand SEK | -30.96% |
| 2017 Q4 | 5.78 Million SEK | 655.69% |
| 2017 Q1 | 302 Thousand SEK | 103.58% |
| 2016 Q1 | 2.7 Million SEK | 7.99% |
| 2016 FY | 501 Thousand SEK | -94.47% |
| 2016 Q3 | 3.33 Million SEK | 0.73% |
| 2016 Q4 | -8.42 Million SEK | -352.9% |
| 2016 Q2 | 3.3 Million SEK | 22.39% |
| 2015 Q1 | 5.09 Million SEK | 939.93% |
| 2015 Q2 | 3.06 Million SEK | -39.84% |
| 2015 Q4 | 2.5 Million SEK | -33.21% |
| 2015 FY | 9.06 Million SEK | 36.38% |
| 2015 Q3 | 3.74 Million SEK | 22.34% |
| 2014 Q1 | 3.25 Million SEK | 208.94% |
| 2014 FY | 6.64 Million SEK | -9.24% |
| 2014 Q4 | -606 Thousand SEK | -117.78% |
| 2014 Q3 | 3.4 Million SEK | 51.06% |
| 2014 Q2 | 2.25 Million SEK | -30.67% |
| 2013 FY | 7.32 Million SEK | 2.76% |
| 2013 Q4 | -2.98 Million SEK | -143.75% |
| 2013 Q1 | 2.9 Million SEK | 381.24% |
| 2013 Q2 | 2.73 Million SEK | -5.81% |
| 2013 Q3 | 6.82 Million SEK | 149.29% |
| 2012 Q3 | 2.82 Million SEK | 0.0% |
| 2012 Q4 | -1.03 Million SEK | -136.56% |
| 2012 FY | 7.12 Million SEK | -30.61% |
| 2011 Q2 | 2.59 Million SEK | 0.0% |
| 2011 FY | 10.27 Million SEK | 17.83% |
| 2010 Q2 | 2.32 Million SEK | 0.0% |
| 2010 FY | 8.71 Million SEK | -2.06% |
| 2009 Q2 | 2.27 Million SEK | 0.0% |
| 2009 FY | 8.9 Million SEK | 9.88% |
| 2008 FY | 8.1 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 101.351% |
| Ziccum AB (publ) | -23.28 Million SEK | 109.323% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 99.373% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 94.805% |
| Mendus AB (publ) | 28.48 Million SEK | 92.379% |
| Genovis AB (publ.) | 54 Million SEK | 95.98% |
| Intervacc AB (publ) | -13.79 Million SEK | 115.739% |
| Active Biotech AB (publ) | -1.67 Million SEK | 229.612% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 78.209% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 91.906% |
| Aptahem AB (publ) | 2.63 Million SEK | 17.473% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 163.461% |
| Kancera AB (publ) | -1.96 Million SEK | 210.483% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -2719.481% |
| Fluicell AB (publ) | 1.73 Million SEK | -24.914% |
| Saniona AB (publ) | 11.78 Million SEK | 81.572% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 142.427% |
| Biovica International AB (publ) | 6.87 Million SEK | 68.431% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 109.324% |
| AcouSort AB (publ) | 8.38 Million SEK | 74.121% |
| Xintela AB (publ) | 78 Thousand SEK | -2683.333% |
| Abliva AB (publ) | -35.66 Million SEK | 106.088% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 101.478% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 22.658% |
| OncoZenge AB (publ) | 3000.00 SEK | -72266.667% |
| Amniotics AB (publ) | -1.93 Million SEK | 212.487% |
| 2cureX AB (publ) | -37.48 Million SEK | 105.791% |
| CombiGene AB (publ) | -21.29 Million SEK | 110.197% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | 613.239% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 99.808% |
| Camurus AB (publ) | 1.58 Billion SEK | 99.863% |
| Corline Biomedical AB | 28.38 Million SEK | 92.35% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 101.769% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 106.308% |
| I-Tech AB | 27.56 Million SEK | 92.124% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 96.94% |
| Cyxone AB (publ) | 2.61 Million SEK | 16.852% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 36.203% |
| Biosergen AB | -456 Thousand SEK | 576.096% |
| Cantargia AB (publ) | -3.45 Million SEK | 162.909% |
| NextCell Pharma AB | -43.74 Million SEK | 104.962% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 123.613% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 80.648% |
| Nanologica AB (publ) | -76 Thousand SEK | 2956.579% |
| SynAct Pharma AB | -778 Thousand SEK | 379.049% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | 1224.87% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 116.801% |
| Lipum AB (publ) | 53 Thousand SEK | -3996.226% |
| BioInvent International AB (publ) | 71.46 Million SEK | 96.962% |
| Alzinova AB (publ) | 19.87 Million SEK | 89.076% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 94.019% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -48.392% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | 14573.333% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | -30.941% |
| Simris Alg AB (publ) | 2 Million SEK | -8.171% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 160.642% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 93.865% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | 306.959% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 30.705% |